CA2413426A1 - Methods and compositions utilizing quinazolinones - Google Patents
Methods and compositions utilizing quinazolinones Download PDFInfo
- Publication number
- CA2413426A1 CA2413426A1 CA002413426A CA2413426A CA2413426A1 CA 2413426 A1 CA2413426 A1 CA 2413426A1 CA 002413426 A CA002413426 A CA 002413426A CA 2413426 A CA2413426 A CA 2413426A CA 2413426 A1 CA2413426 A1 CA 2413426A1
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- alkyl
- chosen
- hydrogen
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Paints Or Removers (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Fats And Perfumes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Quinazolinones of formulae (a, b, c and d) are disclosed. They are useful fo r treating cellular proliferative diseases and disorders associated with KSP kinesin activity.
Claims (64)
1. A method of treating cellular proliferative diseases comprising administering a compound chosen from the group consisting of:
wherein:
R1 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R2 and R2' are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; or R2 and R2' taken together form a 3- to 7-membered ring;
R3 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, oxaalkyl, oxaalkylaryl, substituted oxaalkylaryl, oxaalkylheteroaryl, substituted oxaalkylheteroaryl, R15O- and R15-NH-;
R3' is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, and R15-NH-;
R3" is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R4 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, and R16-alkylene-;
R5, R6, R7 and R8 are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heteroaryl;
R15 is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; and R16 is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl, or a pharmaceutically acceptable salt thereof.
wherein:
R1 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R2 and R2' are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; or R2 and R2' taken together form a 3- to 7-membered ring;
R3 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, oxaalkyl, oxaalkylaryl, substituted oxaalkylaryl, oxaalkylheteroaryl, substituted oxaalkylheteroaryl, R15O- and R15-NH-;
R3' is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, and R15-NH-;
R3" is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R4 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, and R16-alkylene-;
R5, R6, R7 and R8 are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heteroaryl;
R15 is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; and R16 is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl, or a pharmaceutically acceptable salt thereof.
2. A method of treating a disorder associated with KSP kinesin activity comprising administering a compound chosen from the group consisting of:
wherein:
R1 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R2 and R2' are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; or R2 and R2' taken together form a 3- to 7-membered ring;
R3 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, oxaalkyl, oxaalkylaryl, substituted oxaalkylaryl, oxaalkylheteroaryl, substituted oxaalkylheteroaryl, R15O-and R15-NH-;
R3' is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl and R15-NH-;
R3" is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R4 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, and R16-alkylene-;
R5, R6, R7 and R8 are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heteroaryl;
R15 is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; and R16 is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl, or a pharmaceutically acceptable salt thereof.
wherein:
R1 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R2 and R2' are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; or R2 and R2' taken together form a 3- to 7-membered ring;
R3 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, oxaalkyl, oxaalkylaryl, substituted oxaalkylaryl, oxaalkylheteroaryl, substituted oxaalkylheteroaryl, R15O-and R15-NH-;
R3' is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl and R15-NH-;
R3" is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R4 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, and R16-alkylene-;
R5, R6, R7 and R8 are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heteroaryl;
R15 is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; and R16 is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl, or a pharmaceutically acceptable salt thereof.
3. A method of inhibiting KSP kinesin comprising contacting KSP
kinesin with a compound chosen from the group consisting of:
wherein:
R1 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R2 and R2' are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; or R2 and R2' taken together form a 3- to 7-membered ring;
R3 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, oxaalkyl, oxaalkylaryl, substituted oxaalkylaryl, oxaalkylheteroaryl, substituted oxaalkylheteroaryl, R15O-and R15-NH-;
R3' is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl and R15-NH-;
R3" is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R4 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, and R16-alkylene-;
R5, R6, R7 and R8 are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heteroaryl;
R15 is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; and R16 is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl, or a pharmaceutically acceptable salt thereof.
kinesin with a compound chosen from the group consisting of:
wherein:
R1 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R2 and R2' are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; or R2 and R2' taken together form a 3- to 7-membered ring;
R3 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, oxaalkyl, oxaalkylaryl, substituted oxaalkylaryl, oxaalkylheteroaryl, substituted oxaalkylheteroaryl, R15O-and R15-NH-;
R3' is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl and R15-NH-;
R3" is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R4 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, and R16-alkylene-;
R5, R6, R7 and R8 are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heteroaryl;
R15 is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; and R16 is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl, or a pharmaceutically acceptable salt thereof.
4. A method according to claim 1, 2 or 3 wherein:
R1 is chosen from hydrogen, alkyl, aryl, substituted alkyl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, substituted alkylaryl and substituted alkylheteroaryl;
R2 is chosen from hydrogen, alkyl and substituted alkyl;
R2' is hydrogen;
R3 is chosen from alkyl, substituted alkyl, alkylaryl, heteroaryl, aryl, substituted aryl, substituted hereroaryl, substituted oxaalkylaryl R15O- and R15-NH-;
R4 is chosen from alkyl, aryl, alkylaryl, alkylheteroaryl, substituted alkyl, substituted aryl, and R16-alkylene-;
R5 is hydrogen;
R6, R7 and R8 are independently chosen from hydrogen, halogen, methyl, cyano and trifluoromethyl;
R15 is chosen from alkyl, aryl and substituted aryl;
R16 is chosen from alkoxy, amino, alkylamino, dialkylamino and N-heterocyclyl.
R1 is chosen from hydrogen, alkyl, aryl, substituted alkyl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, substituted alkylaryl and substituted alkylheteroaryl;
R2 is chosen from hydrogen, alkyl and substituted alkyl;
R2' is hydrogen;
R3 is chosen from alkyl, substituted alkyl, alkylaryl, heteroaryl, aryl, substituted aryl, substituted hereroaryl, substituted oxaalkylaryl R15O- and R15-NH-;
R4 is chosen from alkyl, aryl, alkylaryl, alkylheteroaryl, substituted alkyl, substituted aryl, and R16-alkylene-;
R5 is hydrogen;
R6, R7 and R8 are independently chosen from hydrogen, halogen, methyl, cyano and trifluoromethyl;
R15 is chosen from alkyl, aryl and substituted aryl;
R16 is chosen from alkoxy, amino, alkylamino, dialkylamino and N-heterocyclyl.
5. A method according to claim 1, 2 or 3 wherein: R2 is chosen from hydrogen, alkyl and substituted alkyl; R2' is hydrogen; and the stereogenic center to which R2 and R2' are attached is of the R configuration.
6. A method according to claim 1, 2 or 3 comprising administering a compound of the formula:
or a pharmaceutically acceptable salt thereof.
or a pharmaceutically acceptable salt thereof.
7. A method according to claim 6 wherein R1 is chosen from hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, alkylaryl and substituted alkylaryl.
8. A method according to claim 7 wherein R1 is chosen from hydrogen, ethyl, propyl, methoxyethyl, naphthyl, phenyl, bromophenyl, chlorophenyl, methoxyphenyl, ethoxyphenyl, tolyl, dimethylphenyl, chorofluorophenyl, methylchlorophenyl, ethylphenyl, phenethyl, benzyl, chlorobenzyl, methylbenzyl, methoxybenzyl, tetrahydrofuranylmethyl and (ethoxycarbonyl)ethyl.
9. A method according to claim 6 wherein R2 is chosen from hydrogen, lower alkyl and substituted lower alkyl; R2' is hydrogen; and the stereogenic center to which R2 and R2' are attached is of the R configuration.
10. A method according to claim 9 wherein R2 is chosen from hydrogen, methyl, ethyl, propyl, methylthioethyl, aminobutyl, (CBZ)aminobutyl, cyclohexylmethyl, benzyloxymethyl, methylsulfinylethyl, methylsulfinylmethyl, hydroxymethyl, benzyl and indolylmethyl.
11. A method according to claim 6 wherein R3 is chosen from C1-C13 alkyl; substituted lower alkyl; aryl, substituted aryl, alkylaryl, alkylheteroaryl, oxaalkylaryl, oxaalkylheteroaryl, substituted alkylaryl, substituted alkylheteroaryl, substituted oxaalkylaryl, and substituted oxaalkylheteroarlyl.
12. A method according to claim 11 wherein R3 is chosen from ethyl, propyl, chloropropyl, butoxy, heptyl, butyl, octyl, tridecanyl, (ethoxycarbonyl)ethyl, dimethylaminoethyl, dimethylaminomethyl, phenyl, naphthyl, halophenyl, dihalophenyl, cyanophenyl, halo(trifluoromethyl)phenyl, chlorophenoxymethyl, methoxyphenyl, carboxyphenyl, ethylphenyl, tolyl, biphenylyl, methylenedioxyphenyl, methylsulfonylphenyl, methoxychlorophenyl, chloronaphthyl, methylhalophenyl, trifluoromethylphenyl, butylphenyl, pentylphenyl, methylnitrophenyl, phenoxymethyl, dimethoxyphenyl, phenylvinyl, nitrochlorophenyl, nitrophenyl, dinitrophenyl, bis(trifluoromethyl)phenyl, benzyloxymethyl, benzyl, furanyl, benzofuranyl, pyridinyl, indolyl, methylpyridinyl, quinolinyl, picolinyl, pyrazolyl, and imidazolyl.
13. A method according to claim 6 wherein R3 is R15-NH- and R15 is chosen from lower alkyl; cyclohexyl; phenyl; and phenyl substituted with halo, lower alkyl, loweralkoxy, or lower alkylthio.
14. A method according to claim 13 wherein R15 is chosen from isopropyl, butyl, cyclohexyl, phenyl, bromophenyl, dichlorophenyl, methoxyphenyl, ethylphenyl, tolyl, trifluoromethylphenyl and methylthiophenyl.
15. A method according to claim 6 wherein R4 is chosen from lower alkyl, substituted lower alkyl, cyclohexyl; phenyl substituted with hydroxy, lower alkoxy or lower alkyl; benzyl; heteroarylmethyl; heteroarylethyl; heteroarylpropyl and alkylene-, wherein R16 is amino, lower alkylamino, di(lower alkyl)amino, lower alkoxy, or N-heterocyclyl.
16. A method according to claim 15 wherein R4 is chosen from methyl, ethyl, propyl, butyl, cyclohexyl, carboxyethyl, carboxymethyl, methoxyethyl, hydroxyethyl, hydroxypropyl, dimethylaminoethyl, dimethylaminopropyl, diethylaminoethyl, diethylaminopropyl, aminopropyl, methylaminopropyl, 2,2-dimethyl-3-(dimethylamino)propyl, 1-cyclohexyl-4-(diethylamino)butyl, aminoethyl, aminobutyl, aminopentyl, aminohexyl, aminoethoxyethyl, isopropylaminopropyl, diisopropylaminoethyl, 1-methyl-4-(diethylamino)butyl, (t-Boc)aminopropyl, hydroxyphenyl, benzyl, methoxyphenyl, methylmethoxyphenyl, dimethylphenyl, tolyl, ethylphenyl, (oxopyrrolidinyl)propyl, (methoxycarbonyl)ethyl, benzylpiperidinyl, pyridinylethyl, pyridinylmethyl, morpholinylethyl, morpholinylpropyl, piperidinyl, azetidinylmethyl, azetidinylpropyl, pyrrolidinylethyl, pyrrolidinylpropyl, piperidinylmethyl, piperidinylethyl, imidazolylpropyl, imidazolylethyl, (ethylpyrrolidinyl)methyl, (methylpyrrolidinyl)ethyl, (methylpiperidinyl)propyl, (methylpiperazinyl)propyl, furanylmethyl and indolylethyl.
17. A method according to claim 6 wherein R1 is chosen from lower alkyl, benzyl, substituted benzyl and substituted phenyl;
R2 is chosen from hydrogen, alkyl, substituted lower alkyl and benzyl;
R2' is hydrogen;
R3 is chosen from substituted phenyl and naphthyl;
R4 is chosen from substituted alkyl and R16-alkylene-;
R5 is hydrogen or halo R6 is hydrogen, methyl or halo;
R7 is hydrogen, halo, lower alkyl, substituted lower alkyl, lower alkoxy or cyano;
R8 is hydrogen or halo; and R16 is chosen from di(lower alkylamino), (lower alkyl)amino, amino, N-heterocyclyl and substituted N-heterocyclyl.
R2 is chosen from hydrogen, alkyl, substituted lower alkyl and benzyl;
R2' is hydrogen;
R3 is chosen from substituted phenyl and naphthyl;
R4 is chosen from substituted alkyl and R16-alkylene-;
R5 is hydrogen or halo R6 is hydrogen, methyl or halo;
R7 is hydrogen, halo, lower alkyl, substituted lower alkyl, lower alkoxy or cyano;
R8 is hydrogen or halo; and R16 is chosen from di(lower alkylamino), (lower alkyl)amino, amino, N-heterocyclyl and substituted N-heterocyclyl.
18. A method according to claim 1, 2 or 3 wherein R1 is benzyl or halobenzyl;
R2 is chosen from ethyl and propyl;
R2' is hydrogen;
R3 is substituted phenyl;
R3' is substituted phenyl;
R3" is substituted phenyl;
R4 is -(CH2)m OH or -(CH2)p-R16 wherein m is 2 or 3 and p is 1-3;
R5 is hydrogen;
R6 is hydrogen;
R7 is halo;
R8 is hydrogen; and R16 is chosen from amino, propylamino, and azetidinyl.
R2 is chosen from ethyl and propyl;
R2' is hydrogen;
R3 is substituted phenyl;
R3' is substituted phenyl;
R3" is substituted phenyl;
R4 is -(CH2)m OH or -(CH2)p-R16 wherein m is 2 or 3 and p is 1-3;
R5 is hydrogen;
R6 is hydrogen;
R7 is halo;
R8 is hydrogen; and R16 is chosen from amino, propylamino, and azetidinyl.
19. A method according to claim 18 wherein the stereogenic center to which R2 and R2' are attached is of the R configuration.
20. A method according to claim 1, 2 or 3 comprising administering a compound of formula:
or a pharmaceutically acceptable salt thereof.
or a pharmaceutically acceptable salt thereof.
21. A method according to claim 20 wherein:
R1 is chosen from hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, naphthyl and substituted phenyl;
R2 is chosen from hydrogen, lower alkyl and substituted lower alkyl and R2' is hydrogen;
R3' is chosen from C1-C13 alkyl; phenyl; naphthyl; phenyl substituted with halo, lower alkyl, lower alkoxy, nitro, methylenedioxy, or trifluoromethyl; biphenylyl, benzyl and heteroaryl; and R4 is chosen from lower alkyl, substituted lower alkyl, cyclohexyl; phenyl substituted with hydroxy, lower alkoxy or lower alkyl; benzyl; heteroarylmethyl;
heteroarylethyl; heteroarylpropyl and R16-alkylene, wherein R16 is amino, (lower alkyl)amino, di(lower alkyl)amino, lower alkoxy, or N-heterocyclyl.
R1 is chosen from hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, naphthyl and substituted phenyl;
R2 is chosen from hydrogen, lower alkyl and substituted lower alkyl and R2' is hydrogen;
R3' is chosen from C1-C13 alkyl; phenyl; naphthyl; phenyl substituted with halo, lower alkyl, lower alkoxy, nitro, methylenedioxy, or trifluoromethyl; biphenylyl, benzyl and heteroaryl; and R4 is chosen from lower alkyl, substituted lower alkyl, cyclohexyl; phenyl substituted with hydroxy, lower alkoxy or lower alkyl; benzyl; heteroarylmethyl;
heteroarylethyl; heteroarylpropyl and R16-alkylene, wherein R16 is amino, (lower alkyl)amino, di(lower alkyl)amino, lower alkoxy, or N-heterocyclyl.
22. A method according to claim 20 wherein R1 is chosen from lower alkyl, benzyl, substituted benzyl and substituted phenyl;
R2 is hydrogen or lower alkyl;
R2' is hydrogen;
R3' is chosen from substituted phenyl and naphthyl;
R4 is R16-alkylene-, hydroxy lower alkyl or carboxy lower alkyl;
R6 and R7 are chosen from hydrogen and halo;
R5 and R8 are hydrogen;
R16 is chosen from di(lower alkylamino), (lower alkyl)amino, amino, piperidinyl, azetidinyl pyrrolidinyl and morpholinyl.
R2 is hydrogen or lower alkyl;
R2' is hydrogen;
R3' is chosen from substituted phenyl and naphthyl;
R4 is R16-alkylene-, hydroxy lower alkyl or carboxy lower alkyl;
R6 and R7 are chosen from hydrogen and halo;
R5 and R8 are hydrogen;
R16 is chosen from di(lower alkylamino), (lower alkyl)amino, amino, piperidinyl, azetidinyl pyrrolidinyl and morpholinyl.
23. A method according to claim 1, 2 or 3 comprising administering a compound of formula:
or a pharmaceutically acceptable salt thereof.
or a pharmaceutically acceptable salt thereof.
24. A method according to claim 23 wherein:
R1 is chosen from hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, naphthyl and substituted phenyl;
R2 is chosen from hydrogen, lower alkyl and substituted lower alkyl and R2' is hydrogen; and R4 is chosen from lower alkyl, cyclohexyl; phenyl substituted with hydroxy, lower alkoxy or lower allcyl; benzyl; heteroarylmethyl; heteroarylethyl;
heteroarylpropyl and R16-alkylene, wherein R16 is di(lower alkyl)amino, alkylamino, amino, lower allcoxy, or N-heterocyclyl.
R1 is chosen from hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, naphthyl and substituted phenyl;
R2 is chosen from hydrogen, lower alkyl and substituted lower alkyl and R2' is hydrogen; and R4 is chosen from lower alkyl, cyclohexyl; phenyl substituted with hydroxy, lower alkoxy or lower allcyl; benzyl; heteroarylmethyl; heteroarylethyl;
heteroarylpropyl and R16-alkylene, wherein R16 is di(lower alkyl)amino, alkylamino, amino, lower allcoxy, or N-heterocyclyl.
25. A method according to claim 23 wherein R1 is chosen from lower alkyl, benzyl, substituted benzyl and substituted phenyl;
R2 is hydrogen or lower alkyl;
R2' is hydrogen;
R4 is R16-alkylene-;
R6 and R7 are chosen from hydrogen and halo;
R5 and R8 are hydrogen; and R16 is chosen from di(lower alkylamino), (lower alkyl)amino, amino, pyrrolidinyl, piperidinyl, imidazolyl and morpholinyl.
R2 is hydrogen or lower alkyl;
R2' is hydrogen;
R4 is R16-alkylene-;
R6 and R7 are chosen from hydrogen and halo;
R5 and R8 are hydrogen; and R16 is chosen from di(lower alkylamino), (lower alkyl)amino, amino, pyrrolidinyl, piperidinyl, imidazolyl and morpholinyl.
26. A method according to claim 1, 2 or 3 comprising administering a compound of formula:
27. A method according to claim 26 wherein:
R1 is chosen from hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, naphthyl and substituted phenyl;
R2 is chosen from hydrogen, lower alkyl and substituted lower alkyl and R2' is hydrogen;
R3" is chosen from C1-C13 alkyl; substituted lower alkyl; phenyl; naphthyl;
phenyl substituted with halo, lower alkyl, lower alkoxy, nitro, methylenedioxy, or trifluoromethyl; biphenylyl; benzyl and heterocyclyl; and R4 is chosen from lower alkyl, substituted lower alkyl; cyclohexyl; phenyl substituted with hydroxy, lower alkoxy or lower alkyl; benzyl; substituted benzyl;
heterocyclyl; heteroarylmethyl; heteroarylethyl; heteroarylpropyl and R16-alkylene, wherein R16 is di(lower alkyl)amino, (lower alkyl)amino, amino, lower alkoxy, or N-heterocyclyl.
R1 is chosen from hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, naphthyl and substituted phenyl;
R2 is chosen from hydrogen, lower alkyl and substituted lower alkyl and R2' is hydrogen;
R3" is chosen from C1-C13 alkyl; substituted lower alkyl; phenyl; naphthyl;
phenyl substituted with halo, lower alkyl, lower alkoxy, nitro, methylenedioxy, or trifluoromethyl; biphenylyl; benzyl and heterocyclyl; and R4 is chosen from lower alkyl, substituted lower alkyl; cyclohexyl; phenyl substituted with hydroxy, lower alkoxy or lower alkyl; benzyl; substituted benzyl;
heterocyclyl; heteroarylmethyl; heteroarylethyl; heteroarylpropyl and R16-alkylene, wherein R16 is di(lower alkyl)amino, (lower alkyl)amino, amino, lower alkoxy, or N-heterocyclyl.
28. A method according to claim 27 wherein R1 is chosen from lower alkyl, benzyl, substituted benzyl and substituted phenyl;
R2 is hydrogen or lower alkyl;
R2' is hydrogen;
R3" is chosen from substituted phenyl, heterocyclyl and naphthyl;
R4 is chosen from subtituted benzyl, heterocyclyl substituted lower alkyl and alkylene-;
R6 and R7 are chosen from hydrogen and halo;
R5 and R8 are hydrogen;
R16 is chosen from di(lower alkylamino), (lower alkyl)amino, amino, pyrrolidinyl, azetidinyl piperidinyl, imidazolyl and morpholinyl.
R2 is hydrogen or lower alkyl;
R2' is hydrogen;
R3" is chosen from substituted phenyl, heterocyclyl and naphthyl;
R4 is chosen from subtituted benzyl, heterocyclyl substituted lower alkyl and alkylene-;
R6 and R7 are chosen from hydrogen and halo;
R5 and R8 are hydrogen;
R16 is chosen from di(lower alkylamino), (lower alkyl)amino, amino, pyrrolidinyl, azetidinyl piperidinyl, imidazolyl and morpholinyl.
29. A method according to claim 28 wherein R1 is benzyl;
R2 is ethyl;
R2' is hydrogen;
R3" is chosen from halophenyl, polyhalophenyl, tolyl, dimethylphenyl, methoxyphenyl, dimethoxyphenyl, cyanophenyl, trifluoromethylphenyl, trifluoromethoxyphenyl, bis(trifluoromethyl)phenyl, carboxyphenyl, t-butylphenyl, methoxycarbonylphenyl, piperidinyl and naphthyl;
R4 is chosen from substituted benzyl, piperidinyl, hydroxy (lower alkyl) and Rlb-allcylene-;
R6 and R7 are chosen from hydrogen and halo;
R5 and R8 are hydrogen;
R16 is chosen from dimethylamino, amino, pyrrolidinyl and piperidinyl.
R2 is ethyl;
R2' is hydrogen;
R3" is chosen from halophenyl, polyhalophenyl, tolyl, dimethylphenyl, methoxyphenyl, dimethoxyphenyl, cyanophenyl, trifluoromethylphenyl, trifluoromethoxyphenyl, bis(trifluoromethyl)phenyl, carboxyphenyl, t-butylphenyl, methoxycarbonylphenyl, piperidinyl and naphthyl;
R4 is chosen from substituted benzyl, piperidinyl, hydroxy (lower alkyl) and Rlb-allcylene-;
R6 and R7 are chosen from hydrogen and halo;
R5 and R8 are hydrogen;
R16 is chosen from dimethylamino, amino, pyrrolidinyl and piperidinyl.
30. A method according to claim 1 or 2 wherein said disease or disorder is chosen from the group consisting of cancer, hyperplasia, restenosis, and cardiac hypertrophy.
31. A compound chosen from the group consisting of:
wherein:
R1 is chosen from hydrogen, alkyl, alkylaryl, alkylheteroaryl, substituted alkyl, substituted alkylaryl, and substituted alkylheteroaryl;
R2 and R2' are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted allcylaryl, substituted heteroaryl, and substituted alkylheteroaryl; or R2 and R2' taken together form a 3- to 7-membered ring;
R3 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, allcylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, oxaalkyl, oxaalkylaryl, substituted oxaalkylaryl, oxaalkylheteroaryl, substituted oxaalkylheteroaryl, R15O- and R15-NH-;
R3" is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R4 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, and R16-alkylene-;
R5, R6, R7 and R8 are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heteroaryl;
R15 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; and R16 is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl, or a pharmaceutically acceptable salt thereof, with the proviso that when R3 is R15-NH-, both of R2 and R4 must be other than hydrogen.
wherein:
R1 is chosen from hydrogen, alkyl, alkylaryl, alkylheteroaryl, substituted alkyl, substituted alkylaryl, and substituted alkylheteroaryl;
R2 and R2' are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted allcylaryl, substituted heteroaryl, and substituted alkylheteroaryl; or R2 and R2' taken together form a 3- to 7-membered ring;
R3 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, allcylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, oxaalkyl, oxaalkylaryl, substituted oxaalkylaryl, oxaalkylheteroaryl, substituted oxaalkylheteroaryl, R15O- and R15-NH-;
R3" is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R4 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, and R16-alkylene-;
R5, R6, R7 and R8 are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heteroaryl;
R15 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; and R16 is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl, or a pharmaceutically acceptable salt thereof, with the proviso that when R3 is R15-NH-, both of R2 and R4 must be other than hydrogen.
32. A compound chosen from the group consisting of:
wherein:
R1 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R2 and R2' are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; or R2 and R2' taken together form a 3- to 7-membered ring;
R3' is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl and R15-NH-;
R4 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, and R16-alkylene-;
R5, R6, R7 and R8 are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heteroaryl;
R15 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; and R16 is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl, or a pharmaceutically acceptable salt thereof.
wherein:
R1 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R2 and R2' are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; or R2 and R2' taken together form a 3- to 7-membered ring;
R3' is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl and R15-NH-;
R4 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, and R16-alkylene-;
R5, R6, R7 and R8 are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heteroaryl;
R15 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; and R16 is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl, or a pharmaceutically acceptable salt thereof.
33. A compound or salt according to claim 31 or 32 wherein:
R1 is chosen from hydrogen, alkyl, aryl, substituted alkyl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, alkylheteroaryl and substituted alkylaryl;
R2 is chosen from hydrogen, alkyl and substituted alkyl; R2' is hydrogen; and the stereogenic center to which R2 and R2' are attached is of the R configuration.
R3 is chosen from alkyl, aryl, alkylaryl, heteroaryl, substituted aryl, substituted alkyl, substituted heteroaryl, oxaalkylaryl, substituted oxaalkylaryl, R15O- and R15-NH-;
R4 is chosen from alkyl, aryl, alkylaryl, alkylheteroaryl, substituted alkyl, substituted aryl, and R16-alkylene-;
R5 is hydrogen;
R6, R7 and R8 are independently chosen from hydrogen, halogen, methyl and trifluoromethyl;
R15 is chosen from alkyl, aryl and substituted aryl; and R16 is chosen from alkoxy, amino, alkylamino, dialkylamino and N-heterocyclyl.
R1 is chosen from hydrogen, alkyl, aryl, substituted alkyl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, alkylheteroaryl and substituted alkylaryl;
R2 is chosen from hydrogen, alkyl and substituted alkyl; R2' is hydrogen; and the stereogenic center to which R2 and R2' are attached is of the R configuration.
R3 is chosen from alkyl, aryl, alkylaryl, heteroaryl, substituted aryl, substituted alkyl, substituted heteroaryl, oxaalkylaryl, substituted oxaalkylaryl, R15O- and R15-NH-;
R4 is chosen from alkyl, aryl, alkylaryl, alkylheteroaryl, substituted alkyl, substituted aryl, and R16-alkylene-;
R5 is hydrogen;
R6, R7 and R8 are independently chosen from hydrogen, halogen, methyl and trifluoromethyl;
R15 is chosen from alkyl, aryl and substituted aryl; and R16 is chosen from alkoxy, amino, alkylamino, dialkylamino and N-heterocyclyl.
34. A compound according to claim 31 of formula:
or a pharmaceutically acceptable salt thereof.
or a pharmaceutically acceptable salt thereof.
35. A compound or salt according to claim 34 wherein R1 is chosen from hydrogen, lower alkyl, substituted lower alkyl, alkylaryl or substituted alkylaryl.
36. A compound or salt according to claim 35 wherein R1 is chosen from hydrogen, ethyl, propyl, methoxyethyl, phenethyl, benzyl, chlorobenzyl, methylbenzyl, methoxybenzyl, tetrahydrofuranylmethyl and (ethoxycarbonyl)ethyl.
37. A compound or salt according to claim 34 wherein R2 is chosen from hydrogen, lower alkyl and substituted lower alkyl; R2' is hydrogen.; and the stereogenic center to which R2 and R2' are attached is of the R configuration.
38. A compound or salt according to claim 37 wherein R2 is chosen from ethyl, i-propyl, c-propyl or t-butyl.
39. A compound or salt according to claim 34 or 37 wherein R3 is chosen from aryl, substituted aryl, alkylaryl, alkylheteroaryl, oxaalkylaryl, oxaalkylheteroaryl, substituted alkylaryl, substituted alkylheteroaryl, substituted oxaalkylaryl or substituted oxaalkylheteroaryl.
40. A compound or salt according to claim 39 wherein R3 is chosen from phenyl, substituted phenyl, benzyl, substituted benzyl, phenylvinyl, substituted phenylvinyl, phenoxy lower alkyl and substituted phenoxy lower alkyl, furanyl, benzofuranyl, pyridinyl, indolyl, methylpyridinyl, quinolinyl, picolinyl, pyrazolyl, and imidazolyl.
41. A compound or salt according to claim 40 wherein R3 is chosen from halophenyl, dihalophenyl, cyanophenyl, halo(trifluoromethyl)phenyl, chlorophenoxymethyl, methoxyphenyl, carboxyphenyl, methylphenyl, ethylphenyl, tolyl, biphenylyl, methylenedioxyphenyl, methylsulfonylphenyl, methoxychlorophenyl, methylhalophenyl, trifluoromethylphenyl, butylphenyl, pentylphenyl, methylnitrophenyl, dimethoxyphenyl, phenylvinyl, nitrochlorophenyl, nitrophenyl, dinitrophenyl, bis(trifluoromethyl)phenyl,
42. A compound or salt according to claim 37 wherein R3 is R15-NH-where R15 is chosen from isopropyl, butyl, cyclohexyl, phenyl, bromophenyl, dichlorophenyl, methoxyphenyl, ethylphenyl, tolyl, trifluoromethylphenyl and.
methylthiophenyl.
methylthiophenyl.
43. A compound or salt according to claim 34, 37 or 39 wherein R4 is chosen from lower alkyl, substituted lower alkyl, and R16-alkylene-, wherein R16 is amino, lower alkylamino, di(lower alkyl)amino, lower alkoxy, or N-heterocyclyl.
44. A compound or salt according to claim 34, 37 or 39 wherein R5, R6, R7 and R8 are chosen from hydrogen, halo, lower alkyl, substituted lower alkyl, lower alkoxy and cyano.
45. A compound or salt according to claim 44 wherein R5, R6 and R8 are hydrogen.
46. A compound or salt according to claim 45 wherein R7 is halo.
47. A compound or salt according to claim 34 wherein:
R1 is chosen from alkylaryl or substituted alkylaryl;
R2 is lower alkyl; R2' is hydrogen; and the stereogenic center to which R2 and R2' are attached is of the R configuration;
R3 is substituted aryl;
R4 is substituted alkyl;
R5 is hydrogen;
R6 is hydrogen;
R7 is halo or cyano; and R8 is hydrogen.
R1 is chosen from alkylaryl or substituted alkylaryl;
R2 is lower alkyl; R2' is hydrogen; and the stereogenic center to which R2 and R2' are attached is of the R configuration;
R3 is substituted aryl;
R4 is substituted alkyl;
R5 is hydrogen;
R6 is hydrogen;
R7 is halo or cyano; and R8 is hydrogen.
48. The compound or salt according to claim 47 wherein:
R1 is benzyl or substituted benzyl;
R2 is i-propyl;
R3 is methyl- and/or halo-substituted phenyl;
R4 is 3-amino-n-propyl;
R5 is hydrogen;
R6 is hydrogen;
R7 is chloro or cyano; and R8 is hydrogen.
R1 is benzyl or substituted benzyl;
R2 is i-propyl;
R3 is methyl- and/or halo-substituted phenyl;
R4 is 3-amino-n-propyl;
R5 is hydrogen;
R6 is hydrogen;
R7 is chloro or cyano; and R8 is hydrogen.
49. The compound or salt according to claim 47 wherein:
R1 is benzyl;
R2 is i-propyl;
R3 is p-fluorophenyl;
R4 is 3-amino-n-propyl;
R5 is hydrogen;
R6 is hydrogen;
R7 is fluoro; and R8 is hydrogen.
R1 is benzyl;
R2 is i-propyl;
R3 is p-fluorophenyl;
R4 is 3-amino-n-propyl;
R5 is hydrogen;
R6 is hydrogen;
R7 is fluoro; and R8 is hydrogen.
50. The compound or salt according to claim 47 wherein:
R1 is benzyl;
R2 is i-propyl;
R3 is p-fluorophenyl;
R4 is 3-amino-n-propyl;
R5 is hydrogen;
R6 is hydrogen;
R7 is chloro; and R8 is hydrogen.
R1 is benzyl;
R2 is i-propyl;
R3 is p-fluorophenyl;
R4 is 3-amino-n-propyl;
R5 is hydrogen;
R6 is hydrogen;
R7 is chloro; and R8 is hydrogen.
51. The compound or salt according to claim 47 wherein:
R1 is benzyl;
R2 is i-propyl;
R3 is 3-fluoro-4-methylphenyl;
R4 is 3-amino-n-propyl;
R5 is hydrogen;
R6 is hydrogen;
R7 is chloro; and R8 is hydrogen.
R1 is benzyl;
R2 is i-propyl;
R3 is 3-fluoro-4-methylphenyl;
R4 is 3-amino-n-propyl;
R5 is hydrogen;
R6 is hydrogen;
R7 is chloro; and R8 is hydrogen.
52. The compound or salt according to claim 47 wherein:
R1 is benzyl;
R2 is i-propyl;
R3 is p-methylphenyl;
R4 is 3-amino-n-propyl;
R5 is hydrogen;
R6 is hydrogen;
R7 is chloro; and R8 is hydrogen.
R1 is benzyl;
R2 is i-propyl;
R3 is p-methylphenyl;
R4 is 3-amino-n-propyl;
R5 is hydrogen;
R6 is hydrogen;
R7 is chloro; and R8 is hydrogen.
53. The compound or salt according to claim 47 wherein:
R1 is benzyl;
R2 is i-propyl;
R3 is p-methylphenyl;
R4 is 3-amino-n-propyl;
R5 is hydrogen;
R6 is hydrogen;
R7 is cyano; and R8 is hydrogen.
R1 is benzyl;
R2 is i-propyl;
R3 is p-methylphenyl;
R4 is 3-amino-n-propyl;
R5 is hydrogen;
R6 is hydrogen;
R7 is cyano; and R8 is hydrogen.
54. A compound according to claim 32 of formula:
or a pharmaceutically acceptable salt thereof.
or a pharmaceutically acceptable salt thereof.
55. A compound according to claim 54 wherein:
R1 is chosen from hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, naphthyl and substituted phenyl;
R2 is chosen from hydrogen, lower alkyl and substituted lower alkyl and R2' is hydrogen;
R3' is chosen from C1-C13 alkyl; phenyl; naphthyl; phenyl substituted with halo, lower alkyl, lower alkoxy, nitro, methylenedioxy, or trifluoromethyl; biphenylyl, benzyl and heteroaryl; and R4 is chosen from lower alkyl, substituted lower alkyl, cyclohexyl; phenyl substituted with hydroxy, lower alkoxy or lower alkyl; benzyl; heteroarylmethyl;
heteroarylethyl; heteroarylpropyl and R16-alkylene, wherein R16 is amino, (lower alkyl)amino, di(lower alkyl)amino, lower alkoxy, or N-heterocyclyl.
R1 is chosen from hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, naphthyl and substituted phenyl;
R2 is chosen from hydrogen, lower alkyl and substituted lower alkyl and R2' is hydrogen;
R3' is chosen from C1-C13 alkyl; phenyl; naphthyl; phenyl substituted with halo, lower alkyl, lower alkoxy, nitro, methylenedioxy, or trifluoromethyl; biphenylyl, benzyl and heteroaryl; and R4 is chosen from lower alkyl, substituted lower alkyl, cyclohexyl; phenyl substituted with hydroxy, lower alkoxy or lower alkyl; benzyl; heteroarylmethyl;
heteroarylethyl; heteroarylpropyl and R16-alkylene, wherein R16 is amino, (lower alkyl)amino, di(lower alkyl)amino, lower alkoxy, or N-heterocyclyl.
56. A compound according to claim 55 wherein:
R1 is chosen from lower alkyl, benzyl, substituted benzyl and substituted phenyl;
R2 is hydrogen or lower alkyl;
R2' is hydrogen;
R3 is chosen from substituted phenyl and naphthyl;
R4 is R16-alkylene-, hydroxy(lower alkyl) or carboxy (lower alkyl);
R7 is hydrogen, fluoro, chloro or methyl;
R5, R6 and R8 are hydrogen;
R16 is chosen from di(lower alkyl)amino, (lower alkyl)amino, amino, pyrrolidinyl and piperidinyl.
R1 is chosen from lower alkyl, benzyl, substituted benzyl and substituted phenyl;
R2 is hydrogen or lower alkyl;
R2' is hydrogen;
R3 is chosen from substituted phenyl and naphthyl;
R4 is R16-alkylene-, hydroxy(lower alkyl) or carboxy (lower alkyl);
R7 is hydrogen, fluoro, chloro or methyl;
R5, R6 and R8 are hydrogen;
R16 is chosen from di(lower alkyl)amino, (lower alkyl)amino, amino, pyrrolidinyl and piperidinyl.
57. A compound according to claim 32 of formula:
or a pharmaceutically acceptable salt thereof.
or a pharmaceutically acceptable salt thereof.
58. A compound or salt according to claim 57 wherein:
R1 is chosen from hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, naphthyl and substituted phenyl;
R2 is chosen from hydrogen, lower alkyl and substituted lower alkyl and R2' is hydrogen; and R4 is chosen from lower alkyl, cyclohexyl; phenyl substituted with hydroxy, lower alkoxy or lower alkyl; benzyl; heteroarylmethyl; heteroarylethyl;
heteroarylpropyl and R16-alkylene, wherein R16 is di(lower alkyl)amino, (lower alkyl)amino, amino, lower alkoxy, or N-heterocyclyl.
R1 is chosen from hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, naphthyl and substituted phenyl;
R2 is chosen from hydrogen, lower alkyl and substituted lower alkyl and R2' is hydrogen; and R4 is chosen from lower alkyl, cyclohexyl; phenyl substituted with hydroxy, lower alkoxy or lower alkyl; benzyl; heteroarylmethyl; heteroarylethyl;
heteroarylpropyl and R16-alkylene, wherein R16 is di(lower alkyl)amino, (lower alkyl)amino, amino, lower alkoxy, or N-heterocyclyl.
59. A compound or salt according to claim 58 wherein:
R1 is chosen from lower alkyl, benzyl, substituted benzyl and substituted phenyl;
R2 is hydrogen or lower alkyl;
R2' is hydrogen;
R4 is R16-alkylene-;
R7 is hydrogen, fluoro, chloro or methyl;
R5, R6 and R8 are hydrogen;
R16 is chosen from di(lower alkylamino), (lower alkyl)amino, amino, pyrrolidinyl, piperidinyl, imidazolyl and morpholinyl.
R1 is chosen from lower alkyl, benzyl, substituted benzyl and substituted phenyl;
R2 is hydrogen or lower alkyl;
R2' is hydrogen;
R4 is R16-alkylene-;
R7 is hydrogen, fluoro, chloro or methyl;
R5, R6 and R8 are hydrogen;
R16 is chosen from di(lower alkylamino), (lower alkyl)amino, amino, pyrrolidinyl, piperidinyl, imidazolyl and morpholinyl.
60. A compound according to claim 31 of formula:
or a pharmaceutically acceptable salt thereof.
or a pharmaceutically acceptable salt thereof.
61. A compound or salt according to claim 60 wherein:
R1 is chosen from hydrogen, lower alkyl, substituted lower alkyl, alkylaryl or substituted alkylaryl;
R2 is chosen from hydrogen, lower allcyl and substituted lower alkyl; R2' is hydrogen;
and the stereogenic center to which R2 and R2' are attached is of the R
configuration;
R3'' is chosen from aryl, substituted aryl, alkylaryl, alkylheteroaryl, oxaalkylaryl, oxaalkylheteroaryl, substituted alkylaryl, substituted alkylheteroaryl, substituted oxaalkylaryl or substituted oxaalkylheteroaryl; and R4 is chosen from lower alkyl, substituted lower alkyl, and R16-alkylene, wherein R16 is di(lower alkyl)amino, (lower alkyl)amino, amino, lower alkoxy, or N-heterocyclyl.
R1 is chosen from hydrogen, lower alkyl, substituted lower alkyl, alkylaryl or substituted alkylaryl;
R2 is chosen from hydrogen, lower allcyl and substituted lower alkyl; R2' is hydrogen;
and the stereogenic center to which R2 and R2' are attached is of the R
configuration;
R3'' is chosen from aryl, substituted aryl, alkylaryl, alkylheteroaryl, oxaalkylaryl, oxaalkylheteroaryl, substituted alkylaryl, substituted alkylheteroaryl, substituted oxaalkylaryl or substituted oxaalkylheteroaryl; and R4 is chosen from lower alkyl, substituted lower alkyl, and R16-alkylene, wherein R16 is di(lower alkyl)amino, (lower alkyl)amino, amino, lower alkoxy, or N-heterocyclyl.
62. A compound according to claim 31 wherein said compound is of a formula as defined in Figure 3.
63. A method of screening for KSP kinesin modulators comprising:
(a) combining a kinesin, a candidate bioactive agent and a compound chosen from the group consisting of:
wherein:
R1 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R2 and R2' are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; or R2 and R2' taken together form a 3- to 7-membered ring;
R3 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, oxaalkyl, oxaalkylaryl, substituted oxaalkylaryl, oxaalkylheteroaryl, substituted oxaalkylheteroaryl, R15O- and R15-NH-;
R3' is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl and R15-NH-;
R3'' is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R4 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, and R16-alkylene-;
R5, R6, R7 and R8 are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heteroaryl;
R15 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; and R16 is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl; and (b) determining the effect of said candidate bioactive agent on the activity of said kinesin.
(a) combining a kinesin, a candidate bioactive agent and a compound chosen from the group consisting of:
wherein:
R1 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R2 and R2' are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; or R2 and R2' taken together form a 3- to 7-membered ring;
R3 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, oxaalkyl, oxaalkylaryl, substituted oxaalkylaryl, oxaalkylheteroaryl, substituted oxaalkylheteroaryl, R15O- and R15-NH-;
R3' is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl and R15-NH-;
R3'' is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R4 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, and R16-alkylene-;
R5, R6, R7 and R8 are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heteroaryl;
R15 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; and R16 is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl; and (b) determining the effect of said candidate bioactive agent on the activity of said kinesin.
64. A method of screening for compounds that bind to KSP kinesin comprising:
(a) combining a kinesin, a candidate bioactive agent and a labeled compound chosen from the group consisting of:
wherein:
R1 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R2 and R2' are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; or R2 and R2' taken together form a 3- to 7-membered ring;
R3 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, oxaalkyl, oxaalkylaryl, substituted oxaalkylaryl, oxaalkylheteroaryl, substituted oxaalkylheteroaryl, R15O- and R15-NH-;
R3' is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl and R15-NH-;
R3'' is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R4 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, and R16-alkylene-;
R5, R6, R7 and R8 are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heteroaryl;
R15 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; and R16 is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl; and (b) determining the binding of said candidate bioactive agent to said kinesin.
(a) combining a kinesin, a candidate bioactive agent and a labeled compound chosen from the group consisting of:
wherein:
R1 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R2 and R2' are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; or R2 and R2' taken together form a 3- to 7-membered ring;
R3 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, oxaalkyl, oxaalkylaryl, substituted oxaalkylaryl, oxaalkylheteroaryl, substituted oxaalkylheteroaryl, R15O- and R15-NH-;
R3' is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl and R15-NH-;
R3'' is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R4 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl, and R16-alkylene-;
R5, R6, R7 and R8 are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heteroaryl;
R15 is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; and R16 is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl; and (b) determining the binding of said candidate bioactive agent to said kinesin.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21310400P | 2000-06-21 | 2000-06-21 | |
US60/213,104 | 2000-06-21 | ||
US09/699,047 | 2000-10-24 | ||
US09/699,047 US6545004B1 (en) | 1999-10-27 | 2000-10-24 | Methods and compositions utilizing quinazolinones |
PCT/US2001/013901 WO2001098278A1 (en) | 2000-06-21 | 2001-04-27 | Methods and compositions utilizing quinazolinones |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2413426A1 true CA2413426A1 (en) | 2001-12-27 |
CA2413426C CA2413426C (en) | 2011-01-04 |
Family
ID=26907773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2413426A Expired - Fee Related CA2413426C (en) | 2000-06-21 | 2001-04-27 | Methods and compositions utilizing quinazolinones |
Country Status (24)
Country | Link |
---|---|
US (7) | US6545004B1 (en) |
EP (2) | EP1707563A3 (en) |
JP (1) | JP4854906B2 (en) |
KR (1) | KR100847788B1 (en) |
CN (1) | CN1229353C (en) |
AT (1) | ATE323684T1 (en) |
AU (3) | AU2001259270B2 (en) |
BR (1) | BR0111898A (en) |
CA (1) | CA2413426C (en) |
CY (1) | CY1105070T1 (en) |
CZ (1) | CZ303007B6 (en) |
DE (1) | DE60118921T2 (en) |
DK (1) | DK1296959T3 (en) |
ES (1) | ES2262649T3 (en) |
HK (1) | HK1053837A1 (en) |
HU (1) | HU229078B1 (en) |
IL (1) | IL153554A (en) |
MX (1) | MXPA02012627A (en) |
NO (1) | NO324440B1 (en) |
NZ (1) | NZ523233A (en) |
PL (1) | PL204525B1 (en) |
PT (1) | PT1296959E (en) |
SI (1) | SI1296959T1 (en) |
WO (1) | WO2001098278A1 (en) |
Families Citing this family (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4965825A (en) | 1981-11-03 | 1990-10-23 | The Personalized Mass Media Corporation | Signal processing apparatus and methods |
US7831204B1 (en) | 1981-11-03 | 2010-11-09 | Personalized Media Communications, Llc | Signal processing apparatus and methods |
ES2272319T3 (en) | 1999-08-27 | 2007-05-01 | Chemocentryx, Inc. | HETEROCICLICAL COMPOUNDS AND METHODS TO MODULATE THE CXCR3 FUNCTION. |
US20070021493A1 (en) * | 1999-09-16 | 2007-01-25 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
US7671200B2 (en) * | 1999-10-27 | 2010-03-02 | Cytokinetics, Inc. | Quinazolinone KSP inhibitors |
CN100381428C (en) * | 1999-10-27 | 2008-04-16 | 赛特凯恩蒂克公司 | Methods and compositions utilizing quianzolinones |
US7230000B1 (en) | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
MXPA03005152A (en) * | 2000-12-11 | 2004-10-14 | Tularik Inc | Cxcr3 antagonists. |
WO2002057244A1 (en) * | 2001-01-19 | 2002-07-25 | Cytokinetics, Inc. | Phenothiazine kinesin inhibitors |
US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
MXPA03011933A (en) | 2001-06-22 | 2004-03-26 | Pfizer Prod Inc | Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers. |
EP2116248A1 (en) * | 2001-09-05 | 2009-11-11 | Minerva Biotechnologies Corporation | Compositions and Methods of Treatment of Cancer |
US7060705B2 (en) | 2001-11-07 | 2006-06-13 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
AU2002366103A1 (en) * | 2001-11-19 | 2003-06-10 | Iconix Pharmaceuticals, Inc. | Modulators of rho c activity |
PT1847534E (en) * | 2001-12-11 | 2011-08-01 | Kyowa Hakko Kirin Co Ltd | Thiadiazoline derivatives for treating cancer |
EP1480980A4 (en) * | 2002-02-15 | 2005-04-20 | Cytokinetics Inc | Syntheses of quinazolinones |
DE60336901D1 (en) * | 2002-03-07 | 2011-06-09 | X Ceptor Therapeutics Inc | CHINAZOLINONE MODULATORS OF NUCLEIC RECEPTORS |
RU2308454C9 (en) * | 2002-04-17 | 2008-05-10 | Цитокинетикс, Инк. | Compounds, compositions based on the same and methods for using thereof |
BR0309892A2 (en) * | 2002-05-09 | 2011-04-05 | Cytokinetics Inc | compound, composition, methods for modulating ksp kinesin activity, inhibiting ksp, and for treating a cell proliferative disease, and use of a compound |
US7214800B2 (en) * | 2002-05-09 | 2007-05-08 | Cytokinetics, Inc. | Compounds, compositions, and methods |
JP2005536475A (en) * | 2002-05-23 | 2005-12-02 | サイトキネティクス・インコーポレーテッド | Compounds, compositions and methods |
AU2003236527A1 (en) * | 2002-06-14 | 2003-12-31 | Cytokinetics, Inc. | Compounds, compositions, and methods |
DE60326248D1 (en) * | 2002-07-17 | 2009-04-02 | Cytokinetics Inc | Compounds, compositions and methods for treating cellular proliferative disorders |
EP1537089A4 (en) * | 2002-07-23 | 2008-04-16 | Cytokinetics Inc | Compounds compositions and methods |
US20040048853A1 (en) * | 2002-08-21 | 2004-03-11 | Gustave Bergnes | Compounds, compositions, and methods |
EP1554265A4 (en) * | 2002-09-13 | 2008-05-07 | Cytokinetics Inc | Compounds, compositions and methods |
JP2006501306A (en) * | 2002-09-30 | 2006-01-12 | サイトキネティクス・インコーポレーテッド | Compounds, compositions and methods |
US7358262B2 (en) * | 2003-01-29 | 2008-04-15 | Whitehead Institute For Biomedical Research | Identification of genotype-selective anti-tumor agents |
SE0300627D0 (en) * | 2003-03-07 | 2003-03-07 | Astrazeneca Ab | Novel fused heterocycles and uses therof |
PL1601673T3 (en) * | 2003-03-07 | 2009-10-30 | Astrazeneca Ab | Fused heterocycles and uses thereof |
AR050920A1 (en) * | 2003-03-07 | 2006-12-06 | Astrazeneca Ab | ENANTIOMERS OF SELECTED FUSED HETEROCICLES AND USES OF THE SAME |
WO2004092123A2 (en) * | 2003-04-10 | 2004-10-28 | Microbia, Inc. | Inhibitors of fungal invasion |
WO2004091547A2 (en) * | 2003-04-10 | 2004-10-28 | Cytokinetics, Inc | Compounds, compositions, and methods |
CN101787000B (en) | 2003-04-18 | 2011-08-03 | 协和发酵麒麟株式会社 | M-stage kinesin inhibitor |
US20080021079A1 (en) * | 2003-05-07 | 2008-01-24 | Han-Jie Zhou | Compounds, Compositions, and Methods |
WO2004103282A2 (en) * | 2003-05-15 | 2004-12-02 | Cytokinetics, Inc. | Compounds, compositions and methods |
US7345046B2 (en) * | 2003-05-30 | 2008-03-18 | Chiron Corporation | Heteroaryl-fused pyrimidinyl compounds as anticancer agents |
KR20060014071A (en) * | 2003-06-10 | 2006-02-14 | 교와 핫꼬 고교 가부시끼가이샤 | Thiadiazoline derivative |
ATE458735T1 (en) * | 2003-06-20 | 2010-03-15 | Novartis Vaccines & Diagnostic | PYRIDINO[1,2-A PYRIMIDINE-4-ONE COMPOUNDS AS ANTI-CANCER AGENT |
CN1835746A (en) * | 2003-08-15 | 2006-09-20 | 默克公司 | Mitotic kinesin inhibitors |
EP1670456A2 (en) * | 2003-10-06 | 2006-06-21 | Cytokinetics, Inc. | Compounds, compositions and methods |
US20070112044A1 (en) * | 2003-10-10 | 2007-05-17 | Kyowa Hakko Kogyo Co., Ltd. | Thiadiazoline derivative |
US20050197327A1 (en) * | 2003-11-03 | 2005-09-08 | Gustave Bergnes | Compounds, compositions, and methods |
JP2007510660A (en) * | 2003-11-07 | 2007-04-26 | サイトキネティクス・インコーポレーテッド | Compounds, compositions and methods |
EP1689724B1 (en) * | 2003-11-25 | 2011-12-21 | Novartis AG | Quinazolinone compounds as anticancer agents |
US7439254B2 (en) | 2003-12-08 | 2008-10-21 | Cytokinetics, Inc. | Compounds, compositions, and methods |
US7662581B1 (en) | 2003-12-18 | 2010-02-16 | Novartis Vaccines And Diagnostics, Inc. | Eg5 co-crystals |
US20070149553A1 (en) * | 2003-12-19 | 2007-06-28 | Arrington Kenneth L | Mitotic kinesin inhibitors |
CN1893951A (en) * | 2003-12-19 | 2007-01-10 | 默克公司 | Mitotic kinesin inhibitors |
CA2547209A1 (en) * | 2003-12-19 | 2005-07-07 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
WO2005095360A1 (en) | 2004-04-02 | 2005-10-13 | Prana Biotechnology Limited | Neurologically-active compounds |
US7795448B2 (en) * | 2004-05-06 | 2010-09-14 | Cytokinetics, Incorporated | Imidazoyl-benzamide anti-cancer agents |
US7504413B2 (en) * | 2004-05-06 | 2009-03-17 | Cytokinetics, Inc. | N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases |
US7618981B2 (en) * | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
EP1753723B1 (en) * | 2004-05-21 | 2008-08-13 | Novartis Vaccines and Diagnostics, Inc. | Substituted quinoline derivatives as mitotic kinesin inhibitors |
WO2005123083A1 (en) * | 2004-06-09 | 2005-12-29 | Cytokinetics, Inc. | Compositions, devices and methods for treating cardiovascular disease |
KR101170925B1 (en) | 2004-06-18 | 2012-08-07 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | N-1-1-benzyl-4-phenyl-1h-imidazol-2-yl-2,2-dimethylpropylbenzamide derivatives and related compounds as kinesin spindle protein ksp inhibitors for the treatment of cancer |
US7375102B2 (en) | 2004-06-28 | 2008-05-20 | Amgen Sf, Llc | Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use |
US7939538B2 (en) * | 2004-06-28 | 2011-05-10 | Amgen Inc. | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases |
US7271271B2 (en) | 2004-06-28 | 2007-09-18 | Amgen Sf, Llc | Imidazolo-related compounds, compositions and methods for their use |
CN101023082A (en) * | 2004-07-22 | 2007-08-22 | 阿斯利康(瑞典)有限公司 | Fused pyrimidones useful in the treatment and the prevention of cancer |
UY29070A1 (en) * | 2004-08-18 | 2006-03-31 | Astrazeneca Ab | FUSIONED HETEROCYCLIC ENANTIOMERS AND THEIR USES |
US20060041128A1 (en) * | 2004-08-18 | 2006-02-23 | Astrazeneca Ab | Selected fused heterocyclics and uses thereof |
WO2006026597A2 (en) * | 2004-08-30 | 2006-03-09 | Smithkline Beecham Corporation | Novel compositions and methods of treatment |
WO2007053135A1 (en) * | 2004-09-14 | 2007-05-10 | Minerva Biotechnologies Corporation | Methods for diagnosis and treatment of cancer |
JP2008517057A (en) * | 2004-10-19 | 2008-05-22 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | Indole and benzimidazole derivatives |
US7449486B2 (en) * | 2004-10-19 | 2008-11-11 | Array Biopharma Inc. | Mitotic kinesin inhibitors and methods of use thereof |
WO2006060737A2 (en) * | 2004-12-03 | 2006-06-08 | Takeda San Diego, Inc. | Mitotic kinesin inhibitors |
ES2409686T3 (en) * | 2005-01-25 | 2013-06-27 | Prolexys Pharmaceuticals, Inc. | Quinoxaline derivatives as antitumor agents |
US20070161644A1 (en) * | 2005-01-25 | 2007-07-12 | Stockwell Brent R | Erastin analogs and uses thereof |
AU2006225637A1 (en) * | 2005-03-22 | 2006-09-28 | Fuji Photo Film Co., Ltd. | Therapeutic agent for hematopoietic tumor |
KR20070113300A (en) * | 2005-03-22 | 2007-11-28 | 교와 핫꼬 고교 가부시끼가이샤 | Agent for treatment of solid tumor |
DE102005024017A1 (en) * | 2005-05-25 | 2006-11-30 | Merck Patent Gmbh | quinazolinones |
JPWO2006137490A1 (en) * | 2005-06-24 | 2009-01-22 | 協和発酵キリン株式会社 | Restenosis treatment |
MY147188A (en) * | 2005-08-09 | 2012-11-14 | Novartis Ag | Substituted imidazole compounds as ksp inhibitors |
WO2007038444A2 (en) * | 2005-09-26 | 2007-04-05 | Merck & Co., Inc. | N-(4-oxo-3,4-dihydroquinazolin-2-yl)butanamides as androgen receptor modulators |
DE102006002065B4 (en) * | 2006-01-16 | 2007-11-29 | Infineon Technologies Austria Ag | Compensation component with reduced and adjustable on-resistance |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
WO2007149476A2 (en) * | 2006-06-19 | 2007-12-27 | Trustees Of Columbia University In The City Of New York | Assays for non-apoptotic cell death and uses thereof |
EP2044222A4 (en) * | 2006-07-27 | 2010-03-03 | Hspa1a as a marker for sensitivity to ksp inhibitors | |
CA2770486C (en) | 2006-09-22 | 2014-07-15 | Merck Sharp & Dohme Corp. | Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
JP2010505811A (en) * | 2006-10-04 | 2010-02-25 | ファイザー・プロダクツ・インク | Pyrido [4,3-d] pyrimidin-4 (3H) -one derivatives as calcium receptor antagonists |
EP2073807A1 (en) | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmaceutical combinations |
WO2008044041A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
KR20090081020A (en) * | 2006-11-13 | 2009-07-27 | 노파르티스 아게 | Substituted pyrazole and triazole compounds as ksp inhibitors |
MX2009007260A (en) * | 2007-01-05 | 2009-07-10 | Novartis Ag | Cyclized derivatives as eg-5 inhibitors. |
PL2109608T3 (en) | 2007-01-10 | 2011-08-31 | Msd Italia Srl | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
US8822497B2 (en) | 2007-03-01 | 2014-09-02 | Novartis Ag | PIM kinase inhibitors and methods of their use |
WO2008144062A1 (en) | 2007-05-21 | 2008-11-27 | Novartis Ag | Csf-1r inhibitors, compositions, and methods of use |
MX2009013815A (en) * | 2007-06-22 | 2010-03-01 | Arqule Inc | Quinazolinone compounds and methods of use thereof. |
WO2009002553A1 (en) * | 2007-06-25 | 2008-12-31 | Prolexys Pharmaceuticals, Inc. | Methods of treating multiple myeloma and resistant cancers |
JP5501227B2 (en) | 2007-06-27 | 2014-05-21 | メルク・シャープ・アンド・ドーム・コーポレーション | 4-Carboxybenzylamino derivatives as histone deacetylase inhibitors |
WO2009141541A2 (en) * | 2008-04-22 | 2009-11-26 | Centre National De La Recherche Scientifique | Novel compositions which inhibit melanogenesis and uses thereof |
JP6043285B2 (en) | 2010-08-02 | 2016-12-14 | サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. | RNA interference-mediated inhibition of catenin (cadherin-binding protein) β1 (CTNNB1) gene expression using small interfering nucleic acids (siNA) |
RU2624045C2 (en) | 2010-08-17 | 2017-06-30 | Сирна Терапьютикс,Инк | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
WO2012051036A1 (en) * | 2010-10-11 | 2012-04-19 | Merck Sharp & Dohme Corp. | Quinazolinone-type compounds as crth2 antagonists |
EP2632472B1 (en) | 2010-10-29 | 2017-12-13 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
EP2455456A1 (en) | 2010-11-22 | 2012-05-23 | Institut Curie | Use of kinesin inhibitors in HIV infection treatment and a method for screening them |
CN103732592A (en) | 2011-04-21 | 2014-04-16 | 默沙东公司 | Insulin-like growth factor-1 receptor inhibitors |
US8940742B2 (en) * | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US20150299696A1 (en) | 2012-05-02 | 2015-10-22 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
CA2895785A1 (en) | 2012-12-21 | 2014-06-26 | Jerry Evarts | Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors |
CA2895782C (en) | 2012-12-21 | 2017-08-22 | Gilead Calistoga Llc | Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors |
AR096621A1 (en) | 2013-06-14 | 2016-01-20 | Gilead Sciences Inc | 3-QUINASA PHOSFATIDYLINOSITOL (PI3K) PHOSFATIDYLINOSITOL INHIBITORS |
EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
NZ718430A (en) | 2013-10-04 | 2021-12-24 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
AU2015231413B2 (en) | 2014-03-19 | 2020-04-23 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of PI3K-gamma mediated disorders |
JO3589B1 (en) | 2014-08-06 | 2020-07-05 | Novartis Ag | Protein kinase c inhibitors and methods of their use |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
MX2018003058A (en) | 2015-09-14 | 2018-08-01 | Infinity Pharmaceuticals Inc | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same. |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
TW201813963A (en) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | Phosphatidylinositol 3-kinase inhibitors |
TW201815787A (en) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | Phosphatidylinositol 3-kinase inhibitors |
TW201825465A (en) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | Phosphatidylinositol 3-kinase inhibitors |
WO2023203254A2 (en) * | 2022-04-22 | 2023-10-26 | Fundamental Pharma Gmbh | Effective means to modulate nmda receptor-mediated toxicity |
Family Cites Families (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1249281B (en) | 1963-05-18 | |||
US3320124A (en) | 1964-07-20 | 1967-05-16 | American Cyanamid Co | Method for treating coccidiosis with quinazolinones |
US3846549A (en) | 1966-09-03 | 1974-11-05 | Boehringer Sohn Ingelheim | Pharmaceutical compositions containing an n-(1-bicyclic aryl-propyl -2)-n-phenyl-piperazine |
BG16042A3 (en) | 1968-11-12 | 1972-05-20 | Nans Ott | METHOD FOR OBTAINING NEW 2(1H)-QUINAZOLINONES |
US3962244A (en) | 1971-01-23 | 1976-06-08 | Hoechst Aktiengesellschaft | Benzene sulfonyl ureas |
US3740442A (en) | 1972-01-14 | 1973-06-19 | Sandoz Ag | 2-isopropylaminobenzophenones in treating inflammation |
US4011324A (en) * | 1976-01-20 | 1977-03-08 | Pfizer Inc. | Esters and amides of pyrimido[4,5-b]quinolin-4(3H)-one-2-carboxylic acids as antiulcer agents |
EP0009008A3 (en) | 1978-09-08 | 1980-05-14 | Ciba-Geigy Ag | Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them |
US4281127A (en) | 1979-07-09 | 1981-07-28 | Hoffmann-La Roche Inc. | Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid derivatives |
DE3177130D1 (en) * | 1980-08-30 | 1990-01-11 | Hoechst Ag | AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEANS CONTAINING THEM AND THE USE THEREOF. |
AU543928B2 (en) | 1981-01-16 | 1985-05-09 | Masayuki Ishikawa | 4(311)-quinazolinone derivatives |
EP0090068A1 (en) | 1982-03-31 | 1983-10-05 | Hans Wenner | Automatic vending machine for newspapers, magazines, foodstuffs and other articles |
GB8524663D0 (en) | 1985-10-07 | 1985-11-13 | Fujisawa Pharmaceutical Co | Quinazoline derivatives |
DE3609598A1 (en) | 1986-03-21 | 1987-10-01 | Hoechst Ag | 2-AZOLYLMETHYL-2-ARYL-1,3-DIOXOLANE AND THE SALTS THEREOF, METHOD FOR THE PRODUCTION THEREOF, MEANS CONTAINING IT AND THEIR USE |
US5187167A (en) | 1986-03-27 | 1993-02-16 | Imperial Chemical Industries Plc | Pharmaceutical compositions comprising quinazolin-4-one derivatives |
GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
US4670560A (en) * | 1986-04-28 | 1987-06-02 | Ortho Pharmaceutical Corporation | Thienopyrimidine-2,4-dione derivatives and intermediates thereof |
US4729996A (en) | 1986-05-29 | 1988-03-08 | Harbor Branch Oceanographic Institution, Inc. | Antitumor compositions and their methods of use |
DE3721855A1 (en) | 1987-03-12 | 1988-09-22 | Merck Patent Gmbh | AMINO ACID DERIVATIVES |
GB8707053D0 (en) | 1987-03-25 | 1987-04-29 | Ici Plc | Anti-tumour agents |
US4808590A (en) | 1987-07-17 | 1989-02-28 | Harbor Branch Oceanographic Institution, Inc. | Antiviral, antitumor and antifungal compositions and their methods of use |
US4866084A (en) | 1987-07-17 | 1989-09-12 | Harbor Branch Oceanographic Institution, Inc. | Topsentin compounds effective against viruses and certain tumors |
JPS6430768A (en) * | 1987-07-28 | 1989-02-01 | Toshiba Corp | Thermal head |
US5756450A (en) | 1987-09-15 | 1998-05-26 | Novartis Corporation | Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms |
US4857530A (en) | 1987-11-03 | 1989-08-15 | Warner-Lambert Company | Substituted quinazolinones as anticancer agents |
GB8820129D0 (en) | 1988-08-24 | 1988-09-28 | Schering Agrochemicals Ltd | Fungicides |
GB8827820D0 (en) | 1988-11-29 | 1988-12-29 | Janssen Pharmaceutica Nv | (1h-azol-1-ylmethyl)substituted quinoline derivatives |
GB8827988D0 (en) | 1988-11-30 | 1989-01-05 | Smith Kline French Lab | Chemical compounds |
US4970226A (en) | 1989-10-03 | 1990-11-13 | Harbor Branch Oceanographic Institution, Inc. | Bis-indole imidazole compounds which are useful antitumor and antimicrobial agents |
US5264439A (en) | 1990-02-13 | 1993-11-23 | Merck & Co., Inc. | Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists incorporating a substituted benzyl element |
AU640016B2 (en) | 1990-05-30 | 1993-08-12 | Imperial Chemical Industries Plc | Hydroquinazoline derivatives |
FR2665159B1 (en) * | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | NEW PYRIDINE AND QUINOLEIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
EP0481614A1 (en) | 1990-10-01 | 1992-04-22 | Merck & Co. Inc. | Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists |
US5411431A (en) * | 1991-01-09 | 1995-05-02 | Crown Gear, B.V. | Method for crown gear grinding by generation |
GB9105771D0 (en) | 1991-03-19 | 1991-05-01 | Cancer Res Inst Royal | Anti-cancer compounds |
US5714493A (en) | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
US5316906A (en) | 1991-08-23 | 1994-05-31 | Molecular Probes, Inc. | Enzymatic analysis using substrates that yield fluorescent precipitates |
US5204354A (en) | 1992-02-14 | 1993-04-20 | Merck & Co., Inc. | Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders |
ATE180785T1 (en) | 1992-03-12 | 1999-06-15 | Smithkline Beecham Plc | CONDENSED INDOLE DERIVATIVES AS 5-HT4 RECEPTOR ANTAGONISTS |
GB9205907D0 (en) | 1992-03-18 | 1992-04-29 | Cancer Res Inst Royal | Anti-cancer compounds |
US5430148A (en) | 1992-03-31 | 1995-07-04 | Agouron Pharmaceuticals, Inc. | Antiproliferative quinazolines |
GB9220571D0 (en) | 1992-09-30 | 1992-11-11 | Ici Plc | Quinazoline derivatives |
US5817662A (en) | 1992-11-09 | 1998-10-06 | Cell Therapeutics, Inc. | Substituted amino alkyl compounds |
US5780476A (en) | 1992-11-16 | 1998-07-14 | Cell Therapeutics, Inc. | Hydroxyl-containing xanthine compounds |
AU6087894A (en) | 1993-01-14 | 1994-08-15 | Cell Therapeutics, Inc. | Acetal or ketal substituted therapeutic compounds |
WO1994016704A1 (en) | 1993-01-19 | 1994-08-04 | Cell Therapeutics, Inc. | Oxime-substituted therapeutic compounds |
US5574057A (en) | 1993-02-03 | 1996-11-12 | University Of Utah Research Foundation | Naamidine A extracted from sea sponges and methods for its use as an anti-tumor agent |
US5401745A (en) | 1993-03-19 | 1995-03-28 | Merck & Co., Inc. | Quinazolinones substituted with phenoxyphenylacetic acid derivatives |
US5837703A (en) | 1993-03-31 | 1998-11-17 | Cell Therapeutics, Inc. | Amino-alcohol substituted cyclic compounds |
US5342944A (en) | 1993-07-19 | 1994-08-30 | American Cyanamid Company | Process for the preparation of 2-alkyl-3,5,6,7- or 8-substituted-4(3H)-quinazolinones |
US20020198326A1 (en) | 1993-11-12 | 2002-12-26 | Taizo Aoyama | Polyolefin resin composition |
CA2113229C (en) | 1994-01-11 | 1999-04-20 | Mark Pines | Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof |
AU1831395A (en) | 1994-01-14 | 1995-08-01 | Cell Therapeutics, Inc. | Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf |
WO1995022546A1 (en) | 1994-02-18 | 1995-08-24 | Cell Therapeutics, Inc. | Intracellular signalling mediators |
AU2096895A (en) | 1994-03-07 | 1995-09-25 | Sugen, Incorporated | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
US5807861A (en) | 1994-03-24 | 1998-09-15 | Cell Therapeutics, Inc. | Amine substituted xanthinyl compounds |
US5801182A (en) | 1994-03-24 | 1998-09-01 | Cell Therapeutics, Inc. | Amine substituted compounds |
US5756502A (en) | 1994-08-08 | 1998-05-26 | Warner-Lambert Company | Quinazolinone derivatives as cholyecystokinin (CCK) ligands |
JPH09165385A (en) * | 1994-08-26 | 1997-06-24 | Kyowa Hakko Kogyo Co Ltd | Quinazoline derivative |
IL110831A (en) | 1994-08-31 | 1998-12-27 | Hadasit Med Res Service | Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis |
US5891879A (en) | 1994-08-31 | 1999-04-06 | Hadasit Medical Research Services & Development Co., Inc. | Quinazolinone-containing pharmaceutical compositions and methods for the use thereof |
IL112125A (en) | 1994-12-22 | 1998-02-08 | Hadasit Med Res Service | Quinazolinone-containing pharmaceutical compositions |
US5753664A (en) | 1995-03-16 | 1998-05-19 | Takeda Chemical Industries, Ltd. | Heterocyclic compounds, their production and use |
DE69600978T2 (en) * | 1995-03-28 | 1999-04-15 | Tanabe Seiyaku Co | Process for the preparation of D-amino acids |
US6245768B1 (en) | 1995-06-05 | 2001-06-12 | Neurogen Corporation | 1-(N′-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligands |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
CA2230237C (en) | 1995-08-30 | 2002-02-26 | Kazuyoshi Miyata | Process for preparing quinazolin-4-one derivative |
US5783577A (en) | 1995-09-15 | 1998-07-21 | Trega Biosciences, Inc. | Synthesis of quinazolinone libraries and derivatives thereof |
WO1997010221A1 (en) | 1995-09-15 | 1997-03-20 | Torrey Pines Institute For Molecular Studies | Synthesis of quinazolinone libraries |
DE19546918A1 (en) | 1995-12-15 | 1997-06-19 | Bayer Ag | Bicyclic heterocycles |
DE19615262A1 (en) | 1996-04-18 | 1997-10-23 | Bayer Ag | Hetero-linked phenylglycinolamides |
BR9709085A (en) | 1996-05-15 | 1999-08-03 | Pfizer | New 2,3-disubstituted-4 (3H) -quinazolinones |
US6008010A (en) | 1996-11-01 | 1999-12-28 | University Of Pittsburgh | Method and apparatus for holding cells |
BR9714222A (en) * | 1996-12-17 | 2000-04-18 | Du Pont | Method for controlling plant diseases |
US5852024A (en) | 1997-02-11 | 1998-12-22 | Hadasit | Treatment and prevention of adhesions |
US6028075A (en) | 1997-02-11 | 2000-02-22 | Pines; Mark | Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies |
US5948775A (en) | 1997-03-19 | 1999-09-07 | American Home Products Corporation | 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones |
US6060479A (en) | 1997-06-09 | 2000-05-09 | Pfizer Inc | Quinazoline-4-one AMPA antagonists |
US6627755B1 (en) | 1997-06-09 | 2003-09-30 | Pfizer Inc | Quinazolin-4-one AMPA antagonists |
ATE303997T1 (en) | 1997-06-09 | 2005-09-15 | Pfizer Prod Inc | CHINAZOLIN-4-ON AMPA ANTAGONISTS |
US5939421A (en) | 1997-07-01 | 1999-08-17 | Signal Pharmaceuticals, Inc. | Quinazoline analogs and related compounds and methods for treating inflammatory conditions |
JP2934628B2 (en) * | 1997-08-21 | 1999-08-16 | 株式会社資生堂 | Quinazolinone derivatives, hair nourishing agents, skin external preparations |
US5972929A (en) | 1997-08-21 | 1999-10-26 | Shiseido Co., Ltd. | Quinazolinone derivative, hair growth promoter and external composition for skin using the same |
IL125950A0 (en) * | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
JP2002500190A (en) * | 1998-01-08 | 2002-01-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Kinesin motor modulators derived from marine sponges |
US6214879B1 (en) * | 1998-03-24 | 2001-04-10 | Virginia Commonwealth University | Allosteric inhibitors of pyruvate kinase |
AU5322399A (en) | 1998-07-27 | 2000-02-21 | President And Fellows Of Harvard College | Method of high-throughput screening of molecules and compounds for their effectson biological and chemical processes |
US6596497B1 (en) * | 1999-03-17 | 2003-07-22 | New York Blood Center, Inc. | Screening of antiviral compounds targeted to the HIV-1 gp41 core structure |
ES2272319T3 (en) | 1999-08-27 | 2007-05-01 | Chemocentryx, Inc. | HETEROCICLICAL COMPOUNDS AND METHODS TO MODULATE THE CXCR3 FUNCTION. |
US6156758A (en) | 1999-09-08 | 2000-12-05 | Isis Pharmaceuticals, Inc. | Antibacterial quinazoline compounds |
AU780846B2 (en) | 1999-09-16 | 2005-04-21 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
CA2385918A1 (en) | 1999-09-28 | 2001-04-05 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Quinazolinones |
KR20020047186A (en) | 1999-09-28 | 2002-06-21 | 플레믹 크리스티안 | Quinazolinones |
US6355637B1 (en) | 1999-10-01 | 2002-03-12 | Advanced Medicine, Inc. | Local anesthetic compounds |
US7230000B1 (en) * | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
CN100381428C (en) * | 1999-10-27 | 2008-04-16 | 赛特凯恩蒂克公司 | Methods and compositions utilizing quianzolinones |
US6495561B2 (en) * | 1999-10-29 | 2002-12-17 | Merck & Co., Inc. | 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists |
US6476041B1 (en) * | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
US6380205B1 (en) | 1999-10-29 | 2002-04-30 | Merck & Co., Inc. | 2-cyclohexyl quinazoline NMDA/NR2B antagonists |
AR026748A1 (en) | 1999-12-08 | 2003-02-26 | Vertex Pharma | A CASPASE INHIBITING COMPOUND, A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, A METHOD FOR THE SYNTHESIS OF THE SAME AND AN INTERMEDIATE COMPOUND PARADICHA SYNTHESIS |
EP1163659B1 (en) | 2000-01-13 | 2006-12-13 | Koninklijke Philips Electronics N.V. | Protecting compressed content after separation from original source |
ES2159488B1 (en) | 2000-03-07 | 2002-04-16 | Uriach & Cia Sa J | PROCEDURE FOR THE PREPARATION OF PIRIMIDONE DERIVATIVES WITH ANTIFUNGIC ACTIVITY. |
AU4966401A (en) | 2000-03-30 | 2001-10-15 | Curis Inc | Small organic molecule regulators of cell proliferation |
US6613798B1 (en) | 2000-03-30 | 2003-09-02 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
US7115653B2 (en) | 2000-03-30 | 2006-10-03 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
ATE502941T1 (en) | 2000-04-25 | 2011-04-15 | Icos Corp | HUMAN PHOSPHATIDYL-INOSITOL-3-KINASE DELTA INHIBITORS |
US20020165221A1 (en) | 2000-10-13 | 2002-11-07 | Baxter Anthony David | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
MXPA03005152A (en) | 2000-12-11 | 2004-10-14 | Tularik Inc | Cxcr3 antagonists. |
DE60208186T2 (en) * | 2001-04-09 | 2006-08-24 | Ortho-Mcneil Pharmaceutical Research Inc. | CHINAZOLIN AND CHINAZOLE-RELATED COMPOUNDS FOR THE TREATMENT OF INTEGRIN-MEDIATED DISEASES |
EP1383771A1 (en) * | 2001-04-20 | 2004-01-28 | Vertex Pharmaceuticals Incorporated | 9-deazaguanine derivatives as inhibitors of gsk-3 |
US7365199B2 (en) * | 2001-04-20 | 2008-04-29 | Fujifilm Corporation | Dye-forming coupler, silver halide photographic light-sensitive material, and azomethine dye compound |
US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
US6936842B2 (en) * | 2001-06-27 | 2005-08-30 | Applied Materials, Inc. | Method and apparatus for process monitoring |
US20030220338A1 (en) * | 2001-07-16 | 2003-11-27 | Watkins Will J. | Fungal efflux pump inhibitors |
US6596723B1 (en) * | 2001-07-16 | 2003-07-22 | Essential Therapeutics, Inc. | Fungal efflux pump inhibitors |
US20030144350A1 (en) * | 2001-07-20 | 2003-07-31 | Adipogenix, Inc. | Fat accumulation-modulation compounds |
JP2005501887A (en) * | 2001-09-05 | 2005-01-20 | ミナーヴァ・バイオテクノロジーズ・コーポレーション | Compositions and uses thereof in the treatment of cancer |
EP2116248A1 (en) * | 2001-09-05 | 2009-11-11 | Minerva Biotechnologies Corporation | Compositions and Methods of Treatment of Cancer |
AU2002366103A1 (en) * | 2001-11-19 | 2003-06-10 | Iconix Pharmaceuticals, Inc. | Modulators of rho c activity |
WO2003043995A1 (en) | 2001-11-20 | 2003-05-30 | Cytokinetics, Inc. | Process for the racemization of chiral quinazolinones |
EP1480980A4 (en) * | 2002-02-15 | 2005-04-20 | Cytokinetics Inc | Syntheses of quinazolinones |
US20030158188A1 (en) * | 2002-02-20 | 2003-08-21 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
US7074805B2 (en) * | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
WO2003084544A2 (en) * | 2002-04-04 | 2003-10-16 | Cv Therapeutics, Inc. | Compounds dor increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis |
US7214800B2 (en) | 2002-05-09 | 2007-05-08 | Cytokinetics, Inc. | Compounds, compositions, and methods |
BR0309892A2 (en) | 2002-05-09 | 2011-04-05 | Cytokinetics Inc | compound, composition, methods for modulating ksp kinesin activity, inhibiting ksp, and for treating a cell proliferative disease, and use of a compound |
JP2005536475A (en) | 2002-05-23 | 2005-12-02 | サイトキネティクス・インコーポレーテッド | Compounds, compositions and methods |
AU2003236527A1 (en) | 2002-06-14 | 2003-12-31 | Cytokinetics, Inc. | Compounds, compositions, and methods |
US20040092561A1 (en) * | 2002-11-07 | 2004-05-13 | Thomas Ruckle | Azolidinone-vinyl fused -benzene derivatives |
EP1537089A4 (en) | 2002-07-23 | 2008-04-16 | Cytokinetics Inc | Compounds compositions and methods |
US20040048853A1 (en) | 2002-08-21 | 2004-03-11 | Gustave Bergnes | Compounds, compositions, and methods |
AU2004272104B2 (en) * | 2003-09-10 | 2011-09-08 | Icagen, Inc | Fused ring heterocycles as potassium channel modulators |
EP1689724B1 (en) * | 2003-11-25 | 2011-12-21 | Novartis AG | Quinazolinone compounds as anticancer agents |
US20050152940A1 (en) * | 2003-12-23 | 2005-07-14 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
WO2005123083A1 (en) * | 2004-06-09 | 2005-12-29 | Cytokinetics, Inc. | Compositions, devices and methods for treating cardiovascular disease |
-
2000
- 2000-10-24 US US09/699,047 patent/US6545004B1/en not_active Expired - Lifetime
- 2000-11-28 US US09/724,644 patent/US6562831B1/en not_active Expired - Fee Related
- 2000-11-28 US US09/724,941 patent/US6831085B1/en not_active Expired - Lifetime
- 2000-11-28 US US09/724,713 patent/US6630479B1/en not_active Expired - Lifetime
- 2000-11-28 US US09/724,897 patent/US7105668B1/en not_active Expired - Fee Related
-
2001
- 2001-04-27 EP EP06075276A patent/EP1707563A3/en not_active Withdrawn
- 2001-04-27 JP JP2002504234A patent/JP4854906B2/en not_active Expired - Fee Related
- 2001-04-27 IL IL153554A patent/IL153554A/en active IP Right Grant
- 2001-04-27 ES ES01932769T patent/ES2262649T3/en not_active Expired - Lifetime
- 2001-04-27 US US10/312,323 patent/US20040023996A1/en not_active Abandoned
- 2001-04-27 BR BR0111898-6A patent/BR0111898A/en not_active Application Discontinuation
- 2001-04-27 PT PT01932769T patent/PT1296959E/en unknown
- 2001-04-27 MX MXPA02012627A patent/MXPA02012627A/en active IP Right Grant
- 2001-04-27 SI SI200130539T patent/SI1296959T1/en unknown
- 2001-04-27 AT AT01932769T patent/ATE323684T1/en active
- 2001-04-27 CN CNB018115829A patent/CN1229353C/en not_active Expired - Lifetime
- 2001-04-27 NZ NZ523233A patent/NZ523233A/en not_active IP Right Cessation
- 2001-04-27 PL PL358412A patent/PL204525B1/en not_active IP Right Cessation
- 2001-04-27 HU HU0301201A patent/HU229078B1/en not_active IP Right Cessation
- 2001-04-27 EP EP01932769A patent/EP1296959B1/en not_active Expired - Lifetime
- 2001-04-27 CA CA2413426A patent/CA2413426C/en not_active Expired - Fee Related
- 2001-04-27 DK DK01932769T patent/DK1296959T3/en active
- 2001-04-27 KR KR1020027017358A patent/KR100847788B1/en not_active IP Right Cessation
- 2001-04-27 AU AU2001259270A patent/AU2001259270B2/en not_active Ceased
- 2001-04-27 CZ CZ20024178A patent/CZ303007B6/en not_active IP Right Cessation
- 2001-04-27 WO PCT/US2001/013901 patent/WO2001098278A1/en active IP Right Grant
- 2001-04-27 DE DE60118921T patent/DE60118921T2/en not_active Expired - Lifetime
- 2001-04-27 AU AU5927001A patent/AU5927001A/en active Pending
-
2002
- 2002-12-20 NO NO20026172A patent/NO324440B1/en not_active IP Right Cessation
-
2003
- 2003-08-26 HK HK03106128A patent/HK1053837A1/en unknown
-
2004
- 2004-07-20 US US10/893,929 patent/US7294634B2/en not_active Expired - Lifetime
-
2006
- 2006-07-07 CY CY20061100942T patent/CY1105070T1/en unknown
- 2006-11-16 AU AU2006236024A patent/AU2006236024A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2413426A1 (en) | Methods and compositions utilizing quinazolinones | |
RU2004135554A (en) | Pyrimidinones, compositions based on them and methods for their use | |
RU2004133325A (en) | COMPOUNDS, COMPOSITIONS ON THEIR BASIS AND WAYS OF THEIR USE | |
SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
KR900701782A (en) | Quinuclidin Therapeutics | |
RU2003138074A (en) | SUBSTITUTED 3-Aryl-5-Aryl- [1,2,4] -Oxadiazoles and their analogues as caspase activators and apoptosis inducers, as well as their use | |
MY132705A (en) | Novel compounds with analgesic effect | |
Peters et al. | Transforming growth factor-β in human glomerular injury | |
ATE197951T1 (en) | NEW IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | |
CA2213759A1 (en) | Method for treating amyloidosis | |
ES2132393T3 (en) | GUANIDINE DERIVATIVES USEFUL IN THERAPEUTICS. | |
SE9802206D0 (en) | Novel compounds | |
SG11201907139UA (en) | Anti-fibrotic compounds | |
WO2002007678A3 (en) | Mu-conopeptides | |
Boger et al. | Synthesis of desacetamidopyrimidoblamic acid and deglyco desacetamidobleomycin A2 | |
Huez et al. | Microinjected interferon does not promote an antiviral response in Hela cells | |
WO2003072049A3 (en) | Induction of hair growth with vascular endothelial growth factor | |
JP2006502230A5 (en) | ||
JP2005539062A5 (en) | ||
HUP0001531A2 (en) | Anthranilic acid derivatives as multi drug resistance modulators | |
WO2005019449A3 (en) | Expression of a recombinant transgene | |
CA2489705A1 (en) | Use of amide derivative of ge 2270 factor a3 for the treatment of acne | |
HU9402298D0 (en) | Reversal of multi-drug resistance by triphenyl-azacycloalkane derivatives | |
AU692458B2 (en) | Use of benzydamine in the treatment of pathological conditions caused by TNF | |
Leeper et al. | The effect of lucanthone (Miracil D) on sublethal radiation damage in Chinese hamster cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20150427 |